Business Times DC: Press Releases

$AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1$

January 7, 2026

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

GlobeNewswire

$AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia$

January 7, 2026

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

GlobeNewswire

GENFIT Announces 2026 Financial Calendar

January 7, 2026

VALLOUREC INITIATES A €200 MILLION SHARE BUYBACK AND TARGETS TOTAL SHAREHOLDER RETURN TO BE AT LEAST €500 MILLION BY AUGUST 2026

GlobeNewswire

January 7, 2026

VALLOUREC LANCE UN PROGRAMME DE RACHAT D’ACTIONS DE 200MILLIONS D’EUROS ET VISE UN RETOUR TOTAL AUX ACTIONNAIRES D’AU MOINS 500MILLIONS D’EUROS D’ICI AOUT 2026

GlobeNewswire

Business Times DC: Press Releases

November 2025

December 2025

January 2026

Press releases published on January 7, 2026

DBIA Announces Region Relations Leadership Team to Support Design-Build Growth Nationwide

Capitol Physical Therapy Unveils New Insights on Meniscus Tears and Knee Injury Recovery

Saxena White P.A. Files Securities Fraud Class Action Against Coupang, Inc., Certain of Its Executives, and Coupang Corp., Expanding the Class Period and Allegations Asserted in Related Action

THEON completes the acquisition of a circa 9.8% stake in Exosens

DEADLINE ALERT for BTDR, GAUZ, ITGR, FFIV: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

mHealth Technologies Market Poised for 17.1% CAGR Growth Through 2030

Asia Forex Mentor Announces AFM Trading Summit Live 2026 – A Free Flagship Global Online Event Setting the 2026 Playbook for Traders and Investors

Transaction in Own Shares

SIA and Bullhorn Announce New IT Staffing Indicator

THE CHOKE POINT: 5 Assets That Control the Bottleneck

Global Card Fraud Losses at $33 Billion

300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

GENFIT Announces 2026 Financial Calendar

GENFIT annonce son calendrier financier pour 2026

Bronstein, Gewirtz & Grossman LLC Urges F5, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Abstrax Releases 2026 Cannabis Flavor & Application Trends to Guide Product Innovation and Portfolio Growth

VALLOUREC INITIATES A €200 MILLION SHARE BUYBACK AND TARGETS TOTAL SHAREHOLDER RETURN TO BE AT LEAST €500 MILLION BY AUGUST 2026

VALLOUREC LANCE UN PROGRAMME DE RACHAT D’ACTIONS DE 200MILLIONS D’EUROS ET VISE UN RETOUR TOTAL AUX ACTIONNAIRES D’AU MOINS 500MILLIONS D’EUROS D’ICI AOUT 2026